Dr. Yu Discusses Optimal Testosterone Suppression

Evan Y. Yu, MD
Published: Thursday, Feb 06, 2014

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses an analysis of optimal testosterone suppression on medical ADT.

There is more and more data to show that lower testosterone levels are optimal. It is currently known that LHRH agonists work well and produce similar clinical outcomes to orchiectomy, but testosterone is not lowered as well and testosterone escapes can occur.

Researchers conducted this analysis to determine the effect on testosterone and free testosterone in patients that underwent orchiectomy. Yu says this is a descriptive study meant to define what testosterone/free testosterone levels would be in a patient who had optimal androgen deprivation therapy (which would be orchiectomy).

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses an analysis of optimal testosterone suppression on medical ADT.

There is more and more data to show that lower testosterone levels are optimal. It is currently known that LHRH agonists work well and produce similar clinical outcomes to orchiectomy, but testosterone is not lowered as well and testosterone escapes can occur.

Researchers conducted this analysis to determine the effect on testosterone and free testosterone in patients that underwent orchiectomy. Yu says this is a descriptive study meant to define what testosterone/free testosterone levels would be in a patient who had optimal androgen deprivation therapy (which would be orchiectomy).




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x